However, by causing frequent episodes of hypoglycemia, progressive loss of effectiveness with chronic use and affecting cardiac potassium channels resulting in diminished response to ischemia, sulfonylureas are mostly used as third-line agents (48). This evidence concerns the gene KCNA3 and ischemia.